Enliven Therapeutics ELVN Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's invested capital?
- Enliven Therapeutics (ELVN) reported invested capital of $321.48M in Q1 2026.
- How has Enliven Therapeutics's invested capital changed year-over-year?
- Enliven Therapeutics's invested capital increased by 71.6% year-over-year, from $187.29M to $321.48M.
- What is the long-term trend for Enliven Therapeutics's invested capital?
- Over 2 years (2021 to 2025), Enliven Therapeutics's invested capital has grown at a 99.7% compound annual growth rate (CAGR), from -$90.54M to $361.1M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).